Chinese vaccine developers have been focused on expanding their COVID-19 pipelines to include targeted vaccines with the ability to tackle new variants. Pharmaceutical companies that develop vaccines with efficacy against Omicron subvariants are expected to gain a significant competitive advantage in China amidst a surge in infections in the East Asian nation. Currently, 87% of the Chinese population has completed a primary homologous vaccination series, whilst only 55% have received a third booster dose, according to the World Health Organization, why effective is the covid-19 vaccine ?
